YD Bio Ltd. is a clinical-stage biotechnology company that operates an integrated healthcare platform spanning regulated diagnostics, clinical services, and commercial therapeutics. The company's core business is driven by its proprietary DNA methylation-based oncology testing programs, which are deployed under a Laboratory Developed Test (LDT) framework in partnership with CLIA-certified and CAP-accredited laboratories in the United States. These diagnostic tools are designed for early cancer detection, including pancreatic cancer screening and breast cancer recurrence monitoring. In addition to diagnostics, YD Bio is advancing regenerative medicine through the development of stem cell- and exosome-based therapeutics, primarily targeting ophthalmologic diseases.
Beyond its proprietary pipeline, YD Bio generates revenue by providing life science distribution and clinical trial supply chain services. This includes procurement, logistics coordination, and compliance support for pharmaceutical and biotechnology partners conducting clinical trials. The company's strategic model relies heavily on partnerships, such as its licensing agreements with EG BioMed for cancer detection technologies and collaborations with 3D Global Biotech for exosome solutions. Headquartered in Taipei, Taiwan, with operations extending to the United States, YD Bio went public in August 2025 following a business combination with the special purpose acquisition company Breeze Holdings Acquisition Corp.
